P1327: RUXOLITINIB COMBINED WITH GLUCOCORTICOID IN THE FIRST-LINE TREATMENT OF GRAFT-VERSUS-HOST DISEASE IN CHILDREN: A SINGLE CENTER RETROSPECTIVE STUDY

P1327: RUXOLITINIB COMBINED WITH GLUCOCORTICOID IN THE FIRST-LINE TREATMENT OF GRAFT-VERSUS-HOST DISEASE IN CHILDREN: A SINGLE CENTER RETROSPECTIVE STUDY

Bibliographic Details
Main Authors:	K. Chen, B. Zou, J.-B. Shao, Q. Liu, N. Zhang, P. Fu, X.-H. Sun, H. Jiang
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000848172.50070.7a

Similar Items

The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study
by: Yang W, et al.
Published: (2021-02-01)

Early utilization of ruxolitinib in acute graft-versus-host disease after liver transplant
by: Siqi Qiu, et al.
Published: (2024-08-01)

Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib
by: Alfonso Rodríguez-Gil, et al.
Published: (2022-05-01)

Management of pediatric steroid-refractory graft versus host disease: Challenges and outcome with ruxolitinib and etanercept
by: Sanjana Sarangarajan, et al.
Published: (2024-01-01)

Life-Threatening Hypertriglyceridemia in a Patient on Ruxolitinib and Sirolimus for Chronic Graft-versus-Host Disease
by: Allison P. Watson, et al.
Published: (2018-01-01)

Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis
by: Shuang Fan, et al.
Published: (2022-08-01)

S231: GLUCOCORTICOID AND GLYCOLYSIS INHIBITORS COOPERATIVELY ABROGATE ACUTE GRAFT-VERSUS-HOST DISEASE
by: Q. wen, et al.
Published: (2022-06-01)

Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients
by: Wei C, et al.
Published: (2021-11-01)

PB2179: RETROSPECTIVE ANALYSIS OF THE EFFICACY AND SAFETY OF RUXOLITINIB IN CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD). A SINGLE-INSTITUTION EXPERIENCE.
by: Ó. Muñiz, et al.
Published: (2022-06-01)

Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease
by: Dong Wang, et al.
Published: (2021-06-01)

P1382: RUXOLITINIB USE IN A REAL WORLD ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE COHORT IN THE NETHERLANDS: A RETROSPECTIVE STUDY
by: L. Van Der Wagen, et al.
Published: (2022-06-01)

Graft-versus-host disease therapy: something else beyond glucocorticoids?
by: Carmen Martínez, et al.
Published: (2011-09-01)

Ruxolitinib plus steroids for acute graft versus host disease: a multicenter, randomized, phase 3 trial
by: Liping Dou, et al.
Published: (2024-10-01)

PB2457: RUXOLITINIB AS TREATMENT IN PATIENTS WITH ACUTE AND CRONIC GRAFT-VERSUS-HOST DISEASE. REAL WORLD EVIDENCE
by: Francisco José Jiménez Nájar, et al.
Published: (2023-08-01)

Ruxolitinib improves hematopoietic regeneration by restoring mesenchymal stromal cell function in acute graft-versus-host disease
by: Yan Lin, et al.
Published: (2023-08-01)

Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
by: Mauricio Sarmiento Maldonado, et al.
Published: (2017-12-01)

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
by: Enrico Maffini, et al.
Published: (2016-08-01)

Physicochemical Stability Study of Oral Suspension Containing Ruxolitinib in Children with Steroid-Refractory Acute Graft-Versus-Host Disease
by: Mélanie Hinterlang, et al.
Published: (2022-01-01)

P1308: RUXOLITINIB AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN APLASTIC ANEMIA PATIENTS
by: Xiaoyu Zhang, et al.
Published: (2023-08-01)

Successful Treatment of Refractory Graft-Versus-Host Disease with Ruxolitinib in a Child after Autologous Stem Cell Transplantation
by: Nurşah Eker, et al.
Published: (2022-06-01)

Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies.
by: Meng-Yun Zhang, et al.
Published: (2022-01-01)

Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons
by: Gabriel Tremblay, et al.
Published: (2021-02-01)

Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial
by: Liping Dou, et al.
Published: (2022-06-01)

A real life use of ruxolitinib in patients with acute and chronic graft versus host disease refractory to corticosteroid treatment in Latin American patients
by: Mauricio Sarmiento, et al.
Published: (2021-07-01)

Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids
by: Joseph Pidala, et al.
Published: (2011-09-01)

A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
by: Jian Chun Matthew Ong, et al.
Published: (2023-05-01)

Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis
by: Ying Chi, et al.
Published: (2021-04-01)

Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease
by: Halvard Bonig, et al.
Published: (2023-11-01)

Meister Eckhart (1260-1327) or the “secularization” of christian mystic experience
by: Alfonso Maestre Sánchez
Published: (2007-01-01)

T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor
by: Hua Jiang, et al.
Published: (2021-10-01)

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
by: Nikolas von Bubnoff, et al.
Published: (2018-11-01)

Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease
by: Halvard Bonig, et al.
Published: (2024-06-01)

Acute graft versus host disease
by: Vogelsang Georgia B, et al.
Published: (2007-09-01)

T cell metabolism in graft-versus-host disease
by: Yujing Zou, et al.
Published: (2020-01-01)

Ruxolitinib, IV Immunoglobulin, and High-Dose Glucocorticoids for Critically Ill Adults With Secondary Hemophagocytic Lymphohistiocytosis: A Single-Center Observational Pilot Study
by: Laura Scholz, MD, et al.
Published: (2024-02-01)

P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS
by: P. Abraham, et al.
Published: (2022-06-01)

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
by: C. Harrison, et al.
Published: (2022-06-01)

Iran and Israel relationship narrated documents Prime Minister (1357 - 1327)
by: ahmad gol mohammadi
Published: (2002-06-01)

S245: RUXOLITINIB IN PEDIATRIC PATIENTS WITH TREATMENT-NAIVE OR STEROID-REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: PRIMARY FINDINGS FROM THE PHASE II REACH5 STUDY
by: Franco Locatelli, et al.
Published: (2023-08-01)

Sirolimus versus imatinib in patients with steroid-refractory chronic graft-versus-host disease: a retrospective analysis of a single-center
by: HE Yundi, et al.
Published: (2021-11-01)